Specifica specializes in the development of advanced antibody libraries and discovery tools, particularly through its patented Generation 3 Antibody Library Discovery Platform. This platform is designed to produce drug-like antibodies with high affinities and favorable developability properties, significantly reducing the need for extensive downstream optimization processes. The Generation 3 libraries utilize clinically validated antibody frameworks combined with natural human antibody sequences, ensuring a diverse range of specific and developable antibodies. Notably, over 80% of antibodies generated from this platform exhibit no measurable biophysical liabilities, making them comparable or superior to existing therapeutic antibodies.

In addition to its core library offerings, Specifica provides a comprehensive suite of services, including custom library creation tailored to partner needs and the integration of its antibody discovery platform into external research programs. The company employs next-generation sequencing for quality control throughout the antibody construction and validation process, ensuring the uniqueness of each library created. Specifica also offers AbXtract, a suite of antibody informatics tools, enhancing its capabilities in antibody discovery and optimization. Through collaborations and technology transfer agreements, such as the recent partnership with Servier and Symphogen, Specifica aims to advance therapeutic development in critical areas like oncology and neuroscience.

United States

Antibody Libraries are the sources from which therapeutic antibodies can be generated using phage or yeast display. Specifica’s Generation 3 platform generates drug like antibodies, with broad diversity, high affinities and few biophysical liabilities, directly from naïve libraries. In addition to in-house designs, Specifica also collaborates closely with partners to create custom libraries in which essential elements are optimized according to partner needs.

Specifica

Company Details